Real-Life Management of Elevated Troponin Level in Patients Treated with Immune Checkpoint Inhibitors
We describe for the first time the management of elevated hs-TnI levels following ICI therapy, which was diagnosed in routine serial surveillance. We found a wide diversity in management, low cardiology involvement, and high interruption of therapy, emphasizing the need for standardized protocol management guidelines.
Authors
- Lior Zornitzki (ORCID: https://orcid.org/0000-0003-3245-2653)
- Yan Topilsky (ORCID: https://orcid.org/0000-0002-6101-8242)
- Dana Viskin (ORCID: https://orcid.org/0000-0001-7537-6078)
- Michal Laufer‐Perl (ORCID: https://orcid.org/0000-0001-9105-2559)
- Shafik Khoury (ORCID: https://orcid.org/0000-0001-5190-9407)
- Ophir Freund (ORCID: https://orcid.org/0000-0002-7272-5284)
- Nicolas Weiss (ORCID: https://orcid.org/0000-0001-5155-196X)
- Shir Frydman (ORCID: https://orcid.org/0000-0002-8882-9109)
- Ofer Havakuk
- Ido Wolf (ORCID: https://orcid.org/0000-0001-9319-7612)
- Shmuel Banai (ORCID: https://orcid.org/0000-0002-3299-2839)
- Maor Tzuberi
- Anna Rozenfeld Hemed
Institutions
- Tel Aviv University (IL)
- Tel Aviv Sourasky Medical Center (IL)
Publication Details
- Journal
- CJC Open
- Published
- 2025-02-13
- DOI
- https://doi.org/10.1016/j.cjco.2025.02.005
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00